CN1297930A - Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide - Google Patents

Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide Download PDF

Info

Publication number
CN1297930A
CN1297930A CN 99124148 CN99124148A CN1297930A CN 1297930 A CN1297930 A CN 1297930A CN 99124148 CN99124148 CN 99124148 CN 99124148 A CN99124148 A CN 99124148A CN 1297930 A CN1297930 A CN 1297930A
Authority
CN
China
Prior art keywords
polypeptide
polynucleotide
hthbs30
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 99124148
Other languages
Chinese (zh)
Inventor
毛裕民
谢毅
裘敏燕
顾叶平
曹跃琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BORONG GENE DEVELOPMENT CO LTD SHANGHAI
Original Assignee
BORONG GENE DEVELOPMENT CO LTD SHANGHAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BORONG GENE DEVELOPMENT CO LTD SHANGHAI filed Critical BORONG GENE DEVELOPMENT CO LTD SHANGHAI
Priority to CN 99124148 priority Critical patent/CN1297930A/en
Priority to PCT/CN2000/000494 priority patent/WO2001040294A1/en
Priority to AU16875/01A priority patent/AU1687501A/en
Publication of CN1297930A publication Critical patent/CN1297930A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention discloses a novel polypeptide, human thrombus protein 30, polynucleotides encoding this polypeptide and DNA recombination process to produce the polypeptide. The present invention also discloses the method of applying the polypeptide in treating various diseases, such as malignant tumor, nosohemia, HIV infection, immunological diseases and inflammations. The present invention also discloses the antagonist resisting the polypeptide and its treatment effect. The present invention also discloses the application of the polynucleotides encoding this polypeptide.

Description

A kind of new polypeptide-human thrombostondin 30 and the polynucleotide of this peptide species of coding
The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide-human thrombostondin 30, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.
(thrombospondin THBS) is a kind of glycoprotein to thrombostondin, and it is hematoblastic alpha particulate component, discharges after thrombocyte is activated, and THBS is incorporated into platelet membrane when divalent cation exists, and it can help hematoblastic cohesion.Except having in thrombocyte the effect, synthetic, the secretion of THBS also all have relation with endotheliocyte, fibroblast, smooth muscle cell etc.(J?Cell?Biol?1982Oct；95(1)：351-4)
THBS comprises following four kinds of functional domains at least: aminoterminal Vitrum AB combined function territory; The type i repeated fragment that comprises the CSVTCG sequence; The type-iii calcium ion that comprises the RGDA sequence is in conjunction with repeated fragment; The cell of C-terminal or thrombocyte combined function territory.Result of experiment shows that the cell combined function territory of the COOH-end of THBS includes at least two sections sequences (GRGDSP and VTCG), can regulate and control THBS and cell or hematoblastic the combination.(J?Biol?Chem?1992?Aug?15；267(23)：16230-6)
On structure, bonded structural domain such as THBS includes can be former with Vitrum AB, sulfatide, Fibrinogen, Fiberonectin, fibrinolysis, type V collagen.
According to results of in situ hybridization, the gene of coding people THBS1 is located in human chromosome 15q15, and THBS1 includes a lot of different functional domains, comprise three multiple subunits (type i, II, III).Concrete result of study shows: the type i repeating structure is by symmetric exons coding; Vitrum AB combined function territory is by an one exons coding, and concrete structure sees also pertinent literature.(Genomics?1990Apr；6(4)：685-91)
The major function of THBS is to cause hematoblastic cohesion.Glycoprotein IIB-IIIa the mixture that is positioned on the film of THBS works as fibrinogen deceptor, when it combines with Fibrinogen, the aggegation of the first step reversible just takes place, under stronger stimulation, thrombostondin discharges from hematoblastic alpha particle, by itself and fibrinogenic interaction, can cause irreversible platelet aggregation of second step.(Annu?RevMed?1986；37：179-86)
THBS1 is a subfamily of thrombostondin.External experimental result shows, that THBS1 can regulating cell is bonding, propagation, move and differentiation.In vivo, the function of THBS1 is studied by homogenic reconstruction experiment, and the result shows that the variation of THBS1 can cause hematoblastic shortage, but the platelet aggregation response of thrombin induction does not reduce.The brain of the mouse that THBS1 lacks, heart, kidney, spleen, stomach, intestines, artery, liver etc. are organized tangible variation, has just found in the lung that lacks THBS1 unusually, can cause the generation of pneumonia and the minimizing of scavenger cell number.(J?Clin?Invest?1998?Mar?1；101(5)：982-92)
In the healing process of skin injury, thrombostondin has important effect, and in addition, it also has important role to the Fibrotic treatment of diseases of eye vesselless tissue (lens).(HistolHistopathol?1999?Oct；14(4)：1309-20)
There are some researches show that also THBS1 is a kind of sticking glycoprotein, it can promote human breast cancer cell and people's vascular endothelial cell bonding, and Vitrum AB combined function territory and type i, II repeating structure functional domain can be regulated above-mentioned effect.(J?Cell?Biochem?1996?Sep?15；62(4)：431-42)
According to amino acid homology result relatively, polypeptide of the present invention is accredited as a kind of new HTHBS30 (HTHBS 30) by deduction, and its homologous protein is the Class1 thrombostondin of house mouse, and albumen number is AB016768.
Because HTHBS30's albumen plays an important role in regulating body critical functions such as cell fission and fetal development as mentioned above, and believe and relate to a large amount of albumen in these regulate processes, thereby need to identify HTHBS30's albumen of more these processes of participation in this area always, particularly identify this proteic aminoacid sequence.The separation of new HTHBS30's protein coding gene also provides the foundation for determining the effect of this albumen under healthy and morbid state.This albumen may constitute the basis of exploitation medical diagnosis on disease and/or curative, and it is very important therefore separating its coding DNA.
An object of the present invention is to provide isolating new polypeptide-human thrombostondin 30 with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides the recombinant vectors of the polynucleotide that contain the HTHBS30 that encodes.
Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain the HTHBS30 that encodes.
Another object of the present invention provides the method for producing the HTHBS30.
Another object of the present invention provides the antibody at polypeptide-human thrombostondin 30 of the present invention.
Another object of the present invention has provided at the simulated compound of polypeptide-human thrombostondin 30 of the present invention, antagonist, agonist, inhibitor.
Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with the HTHBS30.
The present invention relates to a kind of isolated polypeptide, this polypeptide is the people source, and it comprises: polypeptide or its examples of conservative variations, bioactive fragment or derivative with SEQ ID No.2 aminoacid sequence.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.
The invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:
(a) coding has the polynucleotide of the polypeptide of SEQ ID No.2 aminoacid sequence;
(b) with polynucleotide (a) complementary polynucleotide;
(c) with (a) or polynucleotide sequence (b) have the polynucleotide of at least 70% homogeny.
More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 322-1140 position among the SEQ ID NO:1; (b) has the sequence of 1-2429 position among the SEQ ID NO:1.
The present invention relates to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector in addition; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.
The invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.
The invention still further relates to a kind of simulation, activation, antagonism of screening or suppress the method for the compound of HTHBS30's protein-active, it comprises and utilizes polypeptide of the present invention.The invention still further relates to the compound that obtains with this method.
The invention still further relates to a kind of vitro detection and express the relevant disease or the method for disease susceptibility with HTHBS30's abnormal protein, comprise the sudden change in polypeptide described in the detection of biological sample or its coded polynucleotide sequence, perhaps the amount or the biological activity of polypeptide of the present invention in the detection of biological sample.
The present invention also relates to a kind of pharmaceutical composition, it contains polypeptide of the present invention or its stand-in, activator, antagonist or inhibitor and pharmaceutically acceptable carrier.
The invention still further relates to polypeptide of the present invention and/or polynucleotide and be used for the treatment of cancer, developmental character disease or immunological disease or other purposes owing to the medicine of HTHBS30's disease that abnormal expression causes in preparation.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
The following term of using in this specification sheets and claims has following implication unless stated otherwise:
" nucleotide sequence " is meant oligonucleotide, Nucleotide or polynucleotide and fragment or part, also can refer to genome or synthetic DNA or RNA, and they can be strand or two strands, represent sense strand or antisense strand.Similarly, term " aminoacid sequence " is meant oligopeptides, peptide, polypeptide or protein sequence and fragment or part.When " aminoacid sequence " among the present invention related to a kind of aminoacid sequence of naturally occurring protein molecule, this " polypeptide " or " protein " did not mean that aminoacid sequence are restricted to the complete natural amino acid relevant with described protein molecule.
Protein or polynucleotide " variant " are meant a kind of polynucleotide sequence that has the aminoacid sequence of one or more amino acid or Nucleotide change or encode it.Described change can comprise disappearance, insertion or the replacement of amino acid in aminoacid sequence or the nucleotide sequence or Nucleotide.Variant can have " conservative property " and change, and wherein the amino acid of Ti Huaning has structure or the chemical property similar with original acid, as replacing Isoleucine with leucine.Variant also can have non-conservation and change, as replacing glycine with tryptophane.
" disappearance " is meant the disappearance of in aminoacid sequence or nucleotide sequence one or more amino acid or Nucleotide.
" insertion " or " interpolation " is meant that the change in aminoacid sequence or nucleotide sequence causes comparing the increase of one or more amino acid or Nucleotide with naturally occurring molecule." replacement " is meant by different amino acid or Nucleotide and replaces one or more amino acid or Nucleotide.
" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.
" agonist " is meant when combining with the HTHBS30, thereby a kind of this protein that causes changes the molecule of regulating this protein active.Agonist can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with HTHBS30's molecule.
" antagonist " or " inhibition " be meant when combining with the HTHBS30, a kind ofly seals or regulate HTHBS30's the biologic activity or the molecule of immunologic competence.Antagonist and inhibition can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with HTHBS30's molecule.
" adjusting " is meant that HTHBS30's function changes, and comprises the change of the change of the rising of protein active or reduction, binding characteristic and HTHBS30's any other biological property, function or immune property.
" pure basically " is meant and is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying HTHBS30 of standard.Basically pure HTHBS30 can produce single master tape on the irreducibility polyacrylamide gel.The purity available amino end acid sequence of HTHBS30's polypeptide is analyzed.
" complementary " or " complementation " is meant under salt concn that allows and temperature condition by the natural combination of the polynucleotide of base pairing.For example, sequence " C-T-G-A " can combine with complementary sequence " G-A-C-T ".Complementation between two single chain molecules can be part or whole.Complementary degree between the nucleic acid chains has a significant effect for efficient of hybridizing between the nucleic acid chains and intensity.
" homology " is meant the complementary degree, can be portion homologous or complete homology." portion homologous " is meant a kind of part complementary sequence, and it can partly suppress the hybridization of complete complementary sequence and target nucleic acid at least.The inhibition of this hybridization can detect by hybridizing (Southern trace or Northern trace etc.) under the condition that reduces in the severity degree.Basically homologous sequence or hybridization probe can compete and suppress complete homologous sequence and target sequence the condition that reduces of severity degree under combine.This does not mean the conditions permit non-specific binding that the severity degree reduces because the conditional request two sequences that the severity degree reduces mutual be combined into specificity or selectivity interacts.
" homogeny percentage " be meant two or more amino acid or nucleotide sequence relatively in the same or analogous percentage of sequence.The available electron method is measured the homogeny percentage, as passing through MEGALIGN program (Lasergenesoftware package, DNASTAR, Inc., Madison Wis.).The MEGALIGN program can compare two or more sequences (Higgins, D.G. and P.M.Sharp (1988) Gene 73:237-244) according to diverse ways such as Cluster method.The Cluster method is organized the series arrangement cluster by checking the distance between all pairings with each.Then with each bunch with in pairs or become set of dispense.Homogeny percentage between two aminoacid sequences such as sequence A and the sequence B calculates by following formula:
The residue number of mating between sequence A and the sequence B
100
Interval residue number in the residue number-sequence B of interval in the residue number-sequence A of sequence A
Also can be by the Cluster method or with the homogeny percentage (Hein J., (1990) Methods in emzumology 183:625-645) between known method in this area such as the Jotun Hein mensuration nucleotide sequence.
" similarity " is meant the degree that the identical or conservative property of corresponding position amino-acid residue when arranging contrast between the aminoacid sequence replaces.For example be used for amino acid that conservative property replaces, electronegative amino acid can comprise aspartic acid and L-glutamic acid; Positively charged amino acid can comprise Methionin and arginine; Having uncharged head group has similar hydrophilic amino acid can comprise leucine, Isoleucine and Xie Ansuan; Glycine and L-Ala; L-asparagine and glutamine; Serine and Threonine; Phenylalanine and tyrosine.
" antisense " is meant and specific DNA or RNA sequence complementary nucleotide sequence." antisense strand " is meant and " sense strand " complementary nucleic acid chains.
" derivative " is meant HFP or encodes its chemical modification object of nucleic acid.This chemical modification object can be with alkyl, acyl group or the amino hydrogen atom of replacing.The nucleic acid derivative codified keeps the polypeptide of the main biological characteristics of natural molecule.
" antibody " is meant complete antibody molecule and fragment thereof, as Fa, F (ab ') 2And Fv, its energy specificity is in conjunction with HTHBS30's antigenic determinant.
" humanized antibody " is meant that the aminoacid sequence in non-antigen binding domain territory is replaced and becomes more similar to people's antibody, but still keep original in active antibody.
" isolating " speech refers to material is shifted out among its original environment (for example, if spontaneous its natural surroundings that just refers to).Such as it is exactly not to be separated that spontaneous polynucleotide or polypeptide are present in the Live Animals, but same polynucleotide or polypeptide with some or all in natural system with it the material of coexistence separately be exactly isolating.Such polynucleotide may be the parts of a certain carrier, the part that also possible such polynucleotide or polypeptide are a certain composition.Since carrier or composition are not the compositions of its natural surroundings, they remain isolating.
Many As used hereins, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and peptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating HTHBS30 " is meant that the HTHBS30 is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying HTHBS30 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of HTHBS30's polypeptide can be used amino acid sequence analysis.
The invention provides a kind of new polypeptide-human thrombostondin 30, it is made up of the aminoacid sequence shown in the SEQ ID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises HTHBS30's fragment, derivative and analogue.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep identical biological function of HTHBS30 of the present invention or active polypeptide basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.
The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 2429 bases, its open reading frame (322-1140) 272 amino acid of having encoded.Find relatively that according to amino acid sequence homologous the Class1 blood coagulating protein of this polypeptide and house mouse has 47% homology, deducibility goes out the similar 26S Proteasome Structure and Function of Class1 blood coagulating protein that this HTHBS30 has house mouse.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.
The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate coding HTHBS30's polynucleotide.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
Coding HTHBS30's of the present invention special polynucleotide sequence can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of mensuration HTHBS30's transcript; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect the protein product of HTHBS30's genetic expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or directly with the host cell of HTHBS30's encoding sequence through the genetically engineered generation, and the method that produces polypeptide of the present invention through recombinant technology.
Among the present invention, coding HTHBS30's polynucleotide sequence can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains the HTHBS30 that encodes and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, a LaboratoryManual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The PL promotor of lambda particles phage; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, coding HTHBS30's polynucleotide or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results 2Method is handled, and used step is well-known in this area.Alternative is to use MgCl 2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce HTHBS30 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:
(1). with the polynucleotide (or varient) of coding of the present invention people muskelin 30, or with the recombinant expression vector that contains these polynucleotide proper host cell that transforms or transduce;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.
Polypeptide of the present invention (HTHBS30) is a kind of glycoprotein, it is hematoblastic alpha particulate component, HTHBS30's of the present invention major function is to cause hematoblastic cohesion, except in thrombocyte, having the effect, HTHBS30's synthetic, secretion also all have relation with endotheliocyte, fibroblast, smooth muscle cell etc., and that the HTHBS30 can also regulating cell is bonding, propagation, move and process such as differentiation.Discover that in the healing process of skin injury, thrombostondin has important effect.In addition, thrombostondin also has important role to the Fibrotic treatment of diseases of eye vesselless tissue (lens).
HTHBS30 of the present invention can be used for the diagnosis and the treatment of a lot of diseases, comprising: disease in the blood system, malignant tumour, endocrine system disease, nervous system disorders, immunological disease, people's acquired immune deficiency syndrome (AIDS) or the like.
The disease in the blood system that HTHBS30 of the present invention can be used for treating mainly is a hemorrhagic diseases, comprising: the unusual as special property the sent out thrombocytopenia purpura of platelet counts or matter, thrombocytosis, thrombocytasthenia; Coagulation disorders such as various deficiency of coagulation factors (as hemophilia), multifactor due in hemorrhagic diseases such as disseminated inravascular coagulation, the circulation anticoagulative substance increase; Vessel wall is unusual as babington syndrome, supersensitivity purpura vascular purpura; Thrombosis or the like.
Certainly, HTHBS30 of the present invention also has certain effect for the disease in the blood system that other reasons causes, below is exemplified as the disease of concrete available HTHBS30's treatment of the present invention:
Hemorrhagic diseases: hereditary telangiectasis disease, supersensitivity purpura vascular purpura, simple purpura, the special property sent out thrombocytopenia purpura, hemophilia, von Willebrand disease;
Relevant hemopathy has: hepatic diseases, DIC, thrombotic diseases, blood transfusion and transfusion reaction or the like.
Utilize the treatable growth disorders of HTHBS30 of the present invention to comprise: spina bifida, the cranium fissure, anencephalia, the brain bulging, the hole deformity of brain, the Down syndromes, congenital hydrocephalus, the aqueduct deformity, achondroplastic dwarf's disease, spondyloepiphyseal dysplasia disease, pseudocartilage underdevelopment disease, the Langer-Giedion syndromes, chonechondrosteron, hypogenitalism, adrenal,congenital hyperplasia, epispadia, latent, with malformation syndrome of short and small stature (as Conradi syndromes and Danbolt-Closs syndromes), congenital glaucoma or cataract, congenital lens position is unusual, congenital little fissura palpebrae, retinal development is unusual, atrophia nervi optici congenita, congenital sensory nerve hearing loss, ulcuscuris, monster, the Williams syndromes, the Alagille syndromes, shellfish syndrome Weis two or the like.
Utilize the treatable various tumours of HTHBS30 of the present invention to comprise: to comprise that epithelium is (as the substrate epithelium, squama shape epithelium, myxocyte or the like), (as fibrous tissue, fatty tissue, cartilaginous tissue, smooth muscle tissue, blood vessel and lymphatic endothelial tissue or the like), hemopoietic tissue is (as the B cell, the T cell, histocyte or the like), central nervous tissue, peripheral nerve tissue, endocrine tissue, gonadal tissue, the tumour in particular tissues (as dental tissue or the like) source, for example, cancer of the stomach, liver cancer, large bowel cancer, mammary cancer, lung cancer, prostate cancer, cervical cancer, carcinoma of the pancreas, esophagus cancer or the like.
HTHBS30 of the present invention still is a kind of immunomodulator, has immunological enhancement or immunosuppressive action.Polypeptide of the present invention can be used for the treatment of some diseases, and these diseases comprise immunoreactive anergy, or abnormal immune reaction, or the host defend invalid.Polypeptide of the present invention and its antibody also have effect to damage, defective or the imbalance class disease of immuning tissue, particularly for disease of hematopoietic system (as pernicious anemia), tetter (as psoriasis), autoimmune disease (as rheumatoid arthritis), radiation disease and immune lymphocytic generation and adjusting have extremely close relation.
The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check (antagonist) HTHBS30's medicament.Agonist improves HTHBS30's biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the HTHBS30 with mark cultivates with mammalian cell or the film preparation of expressing the HTHBS30.Measure the medicine raising then or check this interactional ability.
HTHBS30's antagonist comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.HTHBS30's antagonist can combine and eliminate its function with the HTHBS30, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.
In screening during as the compound of antagonist, the HTHBS30 can be added during bioanalysis measures, by measuring compound interactional influence between HTHBS30 and its acceptor is determined whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with HTHBS30's bonded peptide molecule obtains.During screening, generally tackle HTHBS30's molecule and carry out mark.
The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at the HTHBS30 antigenic determinant.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the available HTHBS30's direct injection of the production of polyclonal antibody immune animal (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.Preparation HTHBS30's the technology of monoclonal antibody include but not limited to hybridoma technology (Kohler andMilstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing anti-HTHBS30's single-chain antibody.
Anti-HTHBS30's antibody can be used in the immunohistochemistry technology, detects the HTHBS30 in the biopsy specimen.
With the also available labelled with radioisotope of HTHBS30's bonded monoclonal antibody, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of HTHBS30's high-affinity can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing HTHBS30's positive cells.
The disease that antibody among the present invention can be used for treating or prevention is relevant with the HTHBS30.The antibody that gives suitable dosage can stimulate or block HTHBS30's generation or activity.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization HTHBS30 level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The HTHBS30's level that is detected in the test can be with laying down a definition the importance of HTHBS30 in various diseases and be used to the disease of diagnosing the HTHBS30 to work.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
Coding HTHBS30's polynucleotide also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to HTHBS30's nothing expression or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the HTHBS30 who expresses variation, to suppress endogenic HTHBS30's activity.For example, a kind of HTHBS30 of variation can be the HTHBS30 who shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of HTHBS30's expression or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for coding HTHBS30's polynucleotide are transferred in the cell.The method of recombinant viral vector that structure carries coding HTHBS30's polynucleotide is found in existing document (Sambrook, et al.).Reorganization coding HTHBS30's polynucleotide can be packaged in the liposome and be transferred in the cell in addition.
Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Suppress the oligonucleotide (comprising sense-rna and DNA) of HTHBS30 mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
Coding HTHBS30's polynucleotide can be used for the diagnosis with HTHBS30's relative disease.The expression that coding HTHBS30's polynucleotide can be used for detecting HTHBS30 HTHBS30's whether or under morbid state unconventionality expression.As the HTHBS30's that encodes dna sequence dna can be used for biopsy specimen is hybridized to judge HTHBS30's expression situation.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect the HTHBS30 with the special primer of HTHBS30.
The sudden change that detects HTHBS30's gene also can be used for the disease of diagnosing the HTHBS30 to be correlated with.The form of HTHBS30 sudden change comprises that the point mutation compared with normal wild type HTHBS30 dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch MedicalLibrary).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.
Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.The HTHBS30 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to patient's HTHBS30 will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the amino acid sequence homology comparison diagram of the Class1 blood coagulating protein of HTHBS30 of the present invention and house mouse.The top sequence is the HTHBS30, and the below sequence is the Class1 blood coagulating protein of house mouse.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".
Fig. 2 is isolating HTHBS30's polyacrylamide gel electrophoresis figure (SDS-PAGE).30kDa is proteinic molecular weight.The arrow indication is isolated protein band.
{ embodiment }
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: HTHBS30's clone
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dye terminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 1009A07 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 1009A07 clone is 2429bp (shown in Seq ID NO:1), from 322bp to 1140bp the open reading frame (ORF) of a 819bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after pBS-1009A07, encoded protein matter called after HTHBS30.Embodiment 2:cDNA clone's homology retrieval
With HTHBS30's of the present invention sequence and encoded protein sequence thereof, with Blast program (Basiclocal Alignment search tool) [Altschul, SF et al.J.Mol.Biol.1990; 215:403-10], carry out the homology retrieval at databases such as Genbank, Swissport.The gene the highest with HTHBS30's homology of the present invention is the Class1 blood coagulating protein of a kind of known house mouse, and its encoded protein number is AB016768 in the access of Genbank.Protein homology the results are shown in Fig. 1, both height homologies, and its homogeny is 47%; Similarity is 64%.Embodiment 3: with RT-PCR method clones coding HTHBS30's gene
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1：5’-AGGGAACAAAAGCTGGAGCTCCAC-3’(SEQ?ID?NO：3)
Primer2：5’-AGGCCCATGTGTCTATAATTAGAT-3’(SEQ?ID?NO：4)
Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;
Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl 2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-2429bp shown in the SEQ ID NO:1 are identical.Embodiment 4:Northern blotting is analyzed HTHBS30's expression of gene:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- 32P dATP prepares by random priming 32The dna probe of P-mark.Used dna probe is HTHBS30's coding region sequence (322bp to 1140bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark 6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH 2PO 4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 5: reorganization HTHBS30's vivoexpression, separation and purifying
According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3：5’-CATGCTAGCATGCACTTGCGACTGATTTCTTGGC-3’(Seq?ID?No：5)
Primer4：5’-CATGGATCCCTAGTGTACAGTGCTGACTGATACC-3’(Seq?ID?No：6)
5 ' end of these two sections primers contains NheI and BamHI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NheI and BamHI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-1009A07 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-1009A07 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NheI and BamHI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-1009A07) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-1009A07) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein HTHBS30 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 30kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.Embodiment 6 anti-HTHBS30's production of antibodies
With the synthetic specific polypeptide of following HTHBS30: the NH of Peptide synthesizer (PE company product) 2-Met-His-Leu-Arg-Leu-Ile-Ser-Trp-Leu-Phe-Ile-Ile-Leu-Asn-Phe-COOH (SEQ ID NO:7).
Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with the HTHBS30 specifically.
Sequence table
(1) general information:
(ii) denomination of invention: HTHBS30 and encoding sequence thereof
(iii) sequence number: 7
(2) information of SEQ ID NO:1:
(i) sequence signature:
(A) length: 2429bp
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity
(ii) molecule type: cDNA
( xi ) ：SEQ ID NO：1： 1 AGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCCCCGGCGGCTCCTGGAACCCC 61 GGTTCGCGGCGATGCCAGCCACCCCAGCGAAGCCGCCGCAGTTCAGTGCTTGGATAATTT 121 GAAAGTACAATAGTTGGTTTCCCTGTCCACCCGCCCCACTTCGCTTGCCATCACAGCACG 181 CCTATCGGATGTGAGAGGAGAAGTCCCGCTGCTCGGGCACTGTCTATATACGCCTAACAC 241 CTACATATATTTTAAAAACATTAAATATAATTAACAATCAAAAGAAAGAGGAGAAAGGAA 301 GGGAAGCATTACTGGGTTACTATGCACTTGCGACTGATTTCTTGGCTTTTTATCATTTTG 361 AACTTTATGGAATACATCGGCAGCCAAAACGCCTCCCGGGGAAGGCGCCAGCGAAGAATG 421 CATCCTAACGTTAGTCAAGGCTGCCAAGGAGGCTGTGCAACATGCTCAGATTACAATGGA 481 TGTTTGTCATGTAAGCCCAGACTATTTTTTGCTCTGGAAAGAATTGGCATGAAGCAGATT 541 GGAGTATGTCTCTCTTCATGTCCAAGTGGATATTATGGAACTCGATATCCAGATATAAAT 601 AAGTGTACAAAATGCAAAGCTGACTGTGATACCTGTTTCAACAAAAATTTCTGCACAAAA 661 TGTAAAAGTGGATTTTACTTACACCTTGGAAAGTGCCTTGACAATTGCCCAGAAGGGTTG 721 GAAGCCAACAACCATACTATGGAGTGTGTCAGTATTGTGCACTGTGAGGTCAGTGAATGG 781 AATCCTTGGAGTCCATGCACGAAGAAGGGAAAAACATGTGGCTTCAAAAGAGGGACTGAA 841 ACACGGGTCCGAGAAATAATACAGCATCCTTCAGCAAAGGGTAACCTGTGTCCCCCAACA 901 AATGAGACAAGAAAGTGTACAGTGCAAAGGAAGAAGTGTCAGAAGGGAGAACGAGGAAAA 961 AAAGGAAGGGAGAGGAAAAGAAAAAAACCTAATAAAGGAGAAAGTAAAGAAGCAATACCT1021 GACAGCAAAAGTCTGGAATCCAGCAAAGAAATCCCAGAGCAACGAGAAAACAAACAGCAG1081 CAGAAGAAGCGAAAAGTCCAAGATAAACAGAAATCGGTATCAGTCAGCACTGTACACTAG1141 AGGGTTCCATGAGATTATTGTAGACTCATGATGCTGCTATCTCAACCAGATGCCCAGGAC1201 AGGTGCTCTAGCCATTAGGACCACAAATGGACATGTCAGTTATTGCTCTGTCTAAACAAC1261 ATTCCCAGTAGTTGCTATATTCTTCATACAAGCATAGTTAACAACAAAGAGCCAAAAGAT1321 CAAAGAAGGGATACTTTCAGATGGTTGTCTTGTGTGCTTCTCTGCATTTTTAAAAGACAA1381 GACATTCTTGTACATATTATCAATAGGCTATAAGATGTAACAACGAAATGATGACATCTG1441 GAGAAGAAACATCTTTTCCTTATAAAAATGTGTTTTCAAGCTGTTGTTTTAAGAAGCAAA1501 AGATAGTTCTGCAAATTCAAAGATACAGTATCCCTTCAAAACAAATAGGAGTTCAGGGAA1561 GAGAAACATCCTTCAAAGGACAGTGTTGTTTTGACCGGGAGATCTAGAGAGTGCTCAGAA1621 TTAGGGCCTGGCATTTGGAATCACAGGATTTATCATCACAGAAACAACTGTTTTAAGATT1681 AGTTCCATCACTCTCATCCTGTATTTTTATAAGAAACACAAGAGTGCATACCAGAATTGA1741 ATATACCATATGGGATTGGAGAAAGACAAATGTGGAAGAAATCATAGAGCTGGAGACTAC1801 TTTTGTGCTTTACAAAACTGTGAAGGATTGTGGTCACCTGGAACAGGTCTCCAATCTATG1861 TTAGCACTATGTGGCTCAGCCTCTGTTACCCCTTGGATTATATATCAACCTGTAAACATG1921 TGCCTGTAACTTACTTCCAAAAACAAAATCATACTTATTAGAAGAAAATTCTGATTTTAT1981 AGAAAAAAAATAGAGCAAGGAGAATATAACATGTTTGCAAAGTCATGTGCTTTCTTTCTC2041 AATGAGGGAAAAACAATTTTATTACCTGCTTAATGGTCCACCTGGAACTAAAAGGGATAC2101 TATTTTCTAACAAGGTATATCTAGTAGGGGAGAAAGCCACCACAATAAATATATTTGTTA2161 ATAGTTTTTCAAGTTTTGTTCACTCTGTTTTATTGTTTGTTTTATTGAGAAATTCTTACT2221 CTTAGAGACTCATGAATTAAGAAAGAGAATTCTGCTAACTCAGAGAACCTGGTTCCTATG2281 TAATTCAGAATATATTACATTTCTCAGTAATATTTGTTTTTTGAATCCACCTTTATCTGA2341 GCCAATGGAGATTTACTTATAGCGTATTAGGAGATATTTATTCCATTTTCTTATTTTAAT2401 CAACATTCTAATTATAGACACATGGGCCT
(3) information of SEQ ID NO:2:
(i) sequence signature:
(A) length: 272 amino acid
(B) type: amino acid
(D) topological framework: linearity
(ii) molecule type: polypeptide
( xi ) ：SEQ ID NO：2： 1 Met His Leu Arg Leu Ile Ser Trp Leu Phe Ile Ile Leu Asn Phe16 Met Glu Tyr Ile Gly Ser Gln Asn Ala Ser Arg Gly Arg Arg Gln31 Arg Arg Met His Pro Asn Val Ser Gln Gly Cys Gln Gly Gly Cys46 Ala Thr Cys Ser Asp Tyr Asn Gly Cys Leu Ser Cys Lys Pro Arg61 Leu Phe Phe Ala Leu Glu Arg Ile Gly Met Lys Gln Ile Gly Val76 Cys Leu Ser Ser Cys Pro Ser Gly Tyr Tyr Gly Thr Arg Tyr Pro 91 Asp Ile Asn Lys Cys Thr Lys Cys Lys Ala Asp Cys Asp Thr Cys106 Phe Asn Lys Asn Phe Cys Thr Lys Cys Lys Ser Gly Phe Tyr Leu121 His Leu Gly Lys Cys Leu Asp Asn Cys Pro Glu Gly Leu Glu Ala136 Asn Asn His Thr Met Glu Cys Val Ser Ile Val His Cys Glu Val151 Ser Glu Trp Asn Pro Trp Ser Pro Cys Thr Lys Lys Gly Lys Thr166 Cys Gly Phe Lys Arg Gly Thr Glu Thr Arg Val Arg Glu Ile Ile181 Gln His Pro Ser Ala Lys Gly Asn Leu Cys Pro Pro Thr Asn Glu196 Thr Arg Lys Cys Thr Val Gln Arg Lys Lys Cys Gln Lys Gly Glu211 Arg Gly Lys Lys Gly Arg Glu Arg Lys Arg Lys Lys Pro Asn Lys226 Gly Glu Ser Lys Glu Ala Ile Pro Asp Ser Lys Ser Leu Glu Ser241 Ser Lys Glu Ile Pro Glu Gln Arg Glu Asn Lys Gln Gln Gln Lys256 Lys Arg Lys Val Gln Asp Lys Gln Lys Ser Val Ser Val Ser Thr271 Val His
(4) information of SEQ ID NO:3
(i) sequence signature
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide
(xi) sequence description: information (i) sequence signature of SEQ ID NO:3:AGGGAACAAAAGCTGGAGCTCCAC 24 (5) SEQ ID NO:4
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide
(xi) sequence description: information (i) sequence signature of SEQ ID NO:4:AGGCCCATGTGTCTATAATTAGAT 24 (6) SEQ ID NO:5
(A) length: 32 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ ID NO:5:CAGCCATGGCGGGGAAGAAGAATGTTCTGTCG 32 (7) SEQ ID NO:6
(A) length: 29 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: the information of SEQ ID NO:6:CCCGGATCCCGCTGCTTGGCCTTCTTCAC 29 (8) SEQ ID NO:7: (i) sequence signature:
(A) length: 15 amino acid
(B) type: amino acid
(D) topological framework: linearity is molecule type (ii): polypeptide (xi) sequence description: SEQ ID NO:7:Met-Ala-Gly-Lys-Lys-Asn-Val-Leu-Ser-Ser-Leu-Ala-Val-Tyr-Ala 15

Claims (18)

1, a kind of isolated polypeptide-HTHBS30 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ ID NO:2 or active fragments, analogue or the derivative of its polypeptide.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.
4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:
(a) coding have aminoacid sequence shown in the SEQ ID NO:2 polypeptide or its fragment, analogue, derive
The polynucleotide of thing;
(b) with polynucleotide (a) complementary polynucleotide; Or
(c) with (a) or the polynucleotide of at least 70% homogeny (b) are arranged.
5, polynucleotide as claimed in claim 4 is characterized in that described polynucleotide comprise the polynucleotide that coding has aminoacid sequence shown in the SEQID NO:2.
6, polynucleotide as claimed in claim 4, the sequence that it is characterized in that described polynucleotide include the sequence of 1-2429 position among the sequence of 322-1140 position among the SEQ IDNO:1 or the SEQ ID NO:1.
7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.
8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:
(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or
(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.
9, a kind of preparation method with the active polypeptide of HTHBS30 is characterized in that described method comprises:
(a) expressing under HTHBS30's condition, cultivate the described through engineering approaches host cell of claim 8;
(b) from culture, isolate and have the active polypeptide of HTHBS30.
10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with HTHBS30's specificity bonded antibody.
11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses the HTHBS30.
12, compound as claimed in claim 11 is characterized in that it is the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences.
13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used to regulate the HTHBS30 in vivo, the method for external activity.
14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.
15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen HTHBS30's stand-in, agonist, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.
16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.
17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as diagnosis or the treatment disease relevant unusually with the HTHBS30 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.
18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.
CN 99124148 1999-11-29 1999-11-29 Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide Pending CN1297930A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN 99124148 CN1297930A (en) 1999-11-29 1999-11-29 Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide
PCT/CN2000/000494 WO2001040294A1 (en) 1999-11-29 2000-11-27 A novel polypeptide - human thrombospondin-30 and a polynucleoti de encoding the same
AU16875/01A AU1687501A (en) 1999-11-29 2000-11-27 A novel polypeptide - human thrombospondin-30 and a polynucleoti de encoding thesame

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 99124148 CN1297930A (en) 1999-11-29 1999-11-29 Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide

Publications (1)

Publication Number Publication Date
CN1297930A true CN1297930A (en) 2001-06-06

Family

ID=5283239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 99124148 Pending CN1297930A (en) 1999-11-29 1999-11-29 Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide

Country Status (3)

Country Link
CN (1) CN1297930A (en)
AU (1) AU1687501A (en)
WO (1) WO2001040294A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5904101A (en) * 2000-04-05 2001-10-23 Hyseq Inc Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides
CA2623413A1 (en) * 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2063055A1 (en) * 1991-05-22 1992-11-23 Jacob Eyal Peptides having thrombospondin-like activity and their therapeutic use
WO1994013794A1 (en) * 1992-12-04 1994-06-23 Brigham And Women's Hospital, Inc. Human thrombospondin-4

Also Published As

Publication number Publication date
AU1687501A (en) 2001-06-12
WO2001040294A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
CN1296967A (en) Polypeptide-human deaf related gene 14 and polynucleotide for coding said polypeptide
CN1297916A (en) Human bromo structure domain-containing protein 95 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1296974A (en) Polypeptide-human histone H2A.21 and polynucleotide for coding said polypeptide
CN1297999A (en) Human glutaminyl s-RNA synthatase 58 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1297930A (en) Human thrombus protein 30 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1297914A (en) Human zinc-finger protein 58 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1296975A (en) Polypeptide-human ribosomal protein L23 and polynucleotide for coding said polypeptide
CN1297907A (en) Human acetylglactoside transferase 45 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1297931A (en) Human ABC transfer protein 39 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1297902A (en) Human reticulin 80 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1298005A (en) Human sialic transferase 27 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1297904A (en) Human cytokinin inducing-gene expressing protein 25 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1296966A (en) Polypeptide-human SR splicing factor 52 and polynucleotide for coding said polypeptide
CN1296952A (en) Polypeptide-complement receptor 222 and polynucleotide for coding said polypeptide
CN1296976A (en) Polypeptide-human epidermal growth factor receptor protein 25 and polynucleotide for coding said polypeptide
CN1297905A (en) Human ribosomal protein L14.22 as one new kind of polypeptide and polynuceotides encoding this polypeptide
CN1297917A (en) Human zinc-finger protein 38 as one new kind of polypeptide and polynucleotides encoding this polypeptide
CN1293204A (en) Polypeptide-human bromo-functional protein 72 and polynucleotide for coding this polypeptide
CN1296957A (en) Polypeptide-murine tricarboxylic acid vector 39 and polynucleotide for coding said polypeptide
CN1300774A (en) Polypeptide-human thrombotic protein 46 and polynucleotide for coding this polypeptide
CN1296965A (en) Polypeptide-human fibrous growth factor receptor 46 and polynucleotide for coding said polypeptide
CN1352087A (en) New polypeptide-human glycoprotein 42 and polynucleotide for encoding such polypeptide
CN1477195A (en) A polypeptide-human methionyl-tRNA synthetase 29 and polynucleotide for coding said polypeptide
CN1303933A (en) Novel polypeptide-human muscle BOP protein 41 and polynucleotide coding said polypeptide
CN1297913A (en) Human protoplasmic membrane transfer identifying protein 25 as one new kind of polypeptide and polynucleotides encoding this polypeptide

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication